Cell Cycle Control News Today

Tempest Therapeutics (NASDAQ: TPST) experienced a remarkable market upswing of over 2,800%, showcasing one of the most substantial gains this year for a once tiny biotech company trading on the Nasdaq. The surge is undeniably tied to their recent press release. However, decoding the significance of this update can be puzzling for everyday investors who

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new clinical and preclinical data for multiple programs across...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the pirtobrutinib and Verzenio® (abemaciclib) development programs will be...